None
SEDAR Interim Financial Statements
PTEC · Price
[
{
"companyName": "Principal Technologies Inc.",
"reportingPeriodEnd": "2025-10-31",
"reportStatus": "Unaudited",
"auditorName": null,
"auditorKeyMatters": [],
"balanceSheet": {
"cash": 533939,
"amountsReceivable": 86746,
"prepaidExpenseAndDeposits": 59625,
"assetsDiscontinuedOperations": 0,
"totalCurrentAssets": 680310,
"investment": 266810,
"propertyAndEquipment": 12535,
"assetsDiscontinuedOperationsLT": 0,
"totalLongTermAssets": 279345,
"totalAssets": 959655,
"accountsPayableAndAccruedLiabilities": 934938,
"vatRepayment": 141571,
"promissoryNote": 491646,
"researchAndDevelopmentObligation": 0,
"liabilitiesDiscontinuedOperations": 0,
"totalCurrentLiabilities": 1568155,
"liabilitiesDiscontinuedOperationsLT": 0,
"totalLongTermLiabilities": 0,
"shareCapital": 7216849,
"equityReserves": 1899983,
"accumulatedOtherComprehensiveLoss": -3804,
"deficit": -9721528,
"totalEquityAttributableToTheCompany": -608500,
"nonControllingInterest": 0,
"totalEquity": -608500,
"totalLiabilitiesAndEquity": 959655,
"cashPerShare": 0.0110,
"workingCapitalPerShare": -0.0184
},
"incomeStatement": {
"advisoryAndConsulting": 45975,
"directorsFees": 2830,
"managementFees": 398481,
"marketing": 3062,
"professionalFees": 30531,
"regulatoryAndTransferAgent": 2208,
"researchAndDevelopmentCosts": 138672,
"officeAndAdministration": 4759,
"shareBasedCompensation": 18035,
"travel": 6964,
"totalExpenses": 651517,
"netIncomeFromDiscontinuedOperations": 14191,
"lossOnSaleOfDiscontinuedOperations": -152324,
"foreignExchangeGainLoss": 5739,
"financeIncome": 1953,
"totalOtherItems": -130441,
"netLoss": -781958,
"foreignExchangeTranslation": 86670,
"comprehensiveLoss": -695288,
"netLossAttributableToShareholders": -787798,
"netLossAttributableToNonControllingInterest": 5840,
"comprehensiveLossAttributableToShareholders": -753232,
"comprehensiveLossAttributableToNonControllingInterest": 57944,
"basicAndDilutedLossPerShare": -0.01,
"weightedAverageSharesOutstanding": 48343051
},
"cashFlowStatement": {
"netLoss": -781958,
"depreciation": 1243,
"lossOnDisposalOfDiscontinuedOperations": 152324,
"shareBasedCompensation": 18035,
"changeInAmountsReceivable": -41702,
"changeInPrepaidExpenseAndDeposits": -54173,
"changeInResearchAndDevelopmentRecoveries": -470780,
"changeInAccountsPayableAndAccruedLiabilities": 292798,
"cashUsedInOperatingActivitiesContinuingOperations": -884213,
"cashUsedInOperatingActivitiesDiscontinuedOperations": -12283,
"cashUsedInOperatingActivities": -896496,
"stockOptionsIssued": 28240,
"warrantsIssued": 8848,
"issueOfPromissoryNote": 491646,
"shareSubscriptionsReceived": 0,
"cashProvidedByFinancingActivitiesContinuing": 528734,
"cashProvidedByFinancingActivitiesDiscontinued": -4690,
"cashProvidedByFinancingActivities": 524044,
"effectOfForeignExchangeOnCash": -18111,
"changeInCash": -390563,
"cashBeginningOfPeriodContinuing": 924502,
"cashBeginningOfPeriodDiscontinued": 0,
"cashEndOfPeriodDiscontinued": 0,
"cashEnding": 533939
},
"investmentsAndOtherAssets": [
{
"type": "Investment in Associate",
"description": "20% equity interest in E&E CRO Consulting GmbH (clinical research advisory services)",
"ownershipPercentage": 20,
"value": 266810,
"notes": "Retained after sale of controlling interest on October 14, 2025."
}
],
"shareStructure": {
"authorizedShares": "Unlimited",
"issuedShares": 48484247,
"classesOfShares": ["common shares"],
"warrants": [
{
"number": 224800,
"exercisePrice": 0.20,
"expiryDate": "2025-12-21"
},
{
"number": 26667,
"exercisePrice": 0.20,
"expiryDate": "2026-01-18"
},
{
"number": 4000000,
"exercisePrice": 0.30,
"expiryDate": "2026-06-20"
},
{
"number": 2761537,
"exercisePrice": 0.12,
"expiryDate": "2026-07-05"
},
{
"number": 342484,
"exercisePrice": 0.30,
"expiryDate": "2026-11-26"
},
{
"number": 3031561,
"exercisePrice": 0.30,
"expiryDate": "2027-04-30"
}
],
"options": [
{
"number": 40000,
"exercisePrice": 0.12,
"expiryDate": "2026-01-01"
},
{
"number": 100000,
"exercisePrice": 0.16,
"expiryDate": "2026-01-01"
},
{
"number": 500000,
"exercisePrice": 0.16,
"expiryDate": "2031-12-03"
},
{
"number": 100000,
"exercisePrice": 0.16,
"expiryDate": "2032-01-10"
},
{
"number": 250000,
"exercisePrice": 0.14,
"expiryDate": "2032-05-20"
},
{
"number": 2825000,
"exercisePrice": 0.12,
"expiryDate": "2033-07-11"
},
{
"number": 15000,
"exercisePrice": 0.15,
"expiryDate": "2033-08-21"
},
{
"number": 100000,
"exercisePrice": 0.15,
"expiryDate": "2033-10-17"
},
{
"number": 2425000,
"exercisePrice": 0.16,
"expiryDate": "2034-09-02"
},
{
"number": 2350000,
"exercisePrice": 0.20,
"expiryDate": "2035-05-01"
},
{
"number": 100000,
"exercisePrice": 0.22,
"expiryDate": "2035-08-07"
}
],
"rightsConvertibleInstruments": null
},
"managementCompensation": {
"currency": "CAD",
"periods": {
"2025-10-31": {
"consultingAndManagementFees": 745566,
"directorsFees": 2830,
"shareBasedCompensation": 0
},
"2024-10-31": {
"consultingAndManagementFees": 59406,
"directorsFees": 5842,
"shareBasedCompensation": 280018
}
},
"namedIndividuals": [],
"otherRelatedPartyTransactions": []
},
"subsequentEvents": [
{
"eventDate": "November 2025",
"description": "Issued 251,467 common shares at $0.20 each from warrant exercises, 305,000 common shares at $0.12 each from warrant exercises, and 40,000 common shares at $0.12 each from stock option exercises.",
"impactValue": null
},
{
"eventDate": "2025-12-15",
"description": "Completed a private placement of 4,000,000 common shares at $0.30 each for gross proceeds of $1,200,000 for general working capital.",
"impactValue": 1200000
}
]
}
]
More from Principal Technologies Inc
Jun 03, 2026 · 18:18